Incstar Corp., which manufactures and distributesimmunodiagnostic products, said Wednesday that its earningsfor the third quarter ending Sept. 30 will be a lower-than-expected 5 to 6 cents per share.
Orwin L. Carter, president and chief executive officer, saidsales of Incstar's clinical assays product line had not reachedforecasted levels. He said analysts had expected theStillwater, Minn., company to earn about 9 cents per share.
Last year, Incstar's third-quarter income before extraordinaryitems was $539,000, or 4 cents per share.
Incstar stock (AMEX:ISR) closed Wednesday at $7, down $1.50.The company is an affiliate of the Fiat Group of Italy.
(c) 1997 American Health Consultants. All rights reserved.